Study Results Published Showing Advantages with Revlimid in
Publicado: Vie Sep 05, 2014 6:42 pm
Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma
IMF
North Hollywood, CALIFORNIA – September 4, 2014 – The International Myeloma Foundation (IMF) says newly published data confirm REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy,...
Read more:
http://myeloma.org/ArticlePage.action?t ... 43&aTab=-1
IMF
North Hollywood, CALIFORNIA – September 4, 2014 – The International Myeloma Foundation (IMF) says newly published data confirm REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy,...
Read more:
http://myeloma.org/ArticlePage.action?t ... 43&aTab=-1